Cargando…
Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain
The use of supplemental doses of opioids is commonly suggested to manage breakthrough pain. A comparative study of intravenous morphine (IV-MO) and oral transmucosal fentanyl citrate (OTFC) given in doses proportional to the basal opioid regimen was performed in 25 cancer patients receiving stable o...
Autores principales: | Mercadante, S, Villari, P, Ferrera, P, Casuccio, A, Mangione, S, Intravaia, G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359971/ https://www.ncbi.nlm.nih.gov/pubmed/17519902 http://dx.doi.org/10.1038/sj.bjc.6603811 |
Ejemplares similares
-
Safety and Efficacy of Oral Transmucosal Fentanyl Citrate Compared to Morphine Sulphate Immediate Release Tablet in Management of Breakthrough Cancer Pain
por: Bhatnagar, Sushma, et al.
Publicado: (2014) -
Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain
por: Prommer, Eric, et al.
Publicado: (2012) -
A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet
por: Freye, Enno
Publicado: (2008) -
The Prevalence and Characteristics of Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain
por: Mercadante, Sebastiano, et al.
Publicado: (2021) -
Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study
por: Cuomo, Arturo, et al.
Publicado: (2020)